147
Participants
Start Date
August 31, 2015
Primary Completion Date
October 31, 2017
Study Completion Date
December 31, 2017
Osimertinib
80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
docetaxel, bevacizumab
Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao
Qingdao Central Hospital
OTHER